Gene therapy
OBJECTIVESThis course aims to review the current pharmacovigilance requirements for Gene Therapy
LEARNING OUTCOMESAt the end of the course, you will be able to understand the view of the US regulators on Gene Therapy and EMA perspective of the advance therapies. In addition, it will provide you with an understanding on Pharmacovigilance and ethical complexities associated with them.
|
|
AUTHORS
![]() |
Nasop Experts Group ISoP's North American chapter |
![]() |
Dr. Sepideh Habibi Global Head of Pharmacovigilance and Risk Management |